A phase 1 study of PARP-inhibitor ABT-767 in advanced solid tumors with BRCA1/2 mutations and high-grade serous ovarian, fallopian tube, or primary peritoneal cancer.

Invest New Drugs · 2018 · PMC6153550 · PMID 29313279

Europe PMC DOI

hedged sentence

0.1000

closest p · 2.0× alpha

0.1000

boldest claim

The sentences

a trend toward significancep < 0.1so close (0.05 < p ≤ 0.1)

Predictors of response In univariate analysis, platinum sensitivity (compared to platinum resistant population) was a significant covariate ( p < 0.01) affecting best tumor response by RECIST, whereas ABT-767 dose and BRCA mutational status (germline compared to non-germline) showed a trend toward significance ( p < 0.1) (Supplemental Fig. 3 ).

also in 3,729 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.